Skip to main content
EMV CAPITAL PLC logo

EMV CAPITAL PLC — Investor Relations & Filings

Ticker · EMVC ISIN · GB00BN4R5Q82 LEI · 213800N5WD46G1Y7I458 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2016-04-05 Board/Management Inform…
Country GB United Kingdom
Listing IL EMVC

About EMV CAPITAL PLC

https://www.emvcapital.com/

EMV Capital PLC is a venture capital investment group specializing in deep tech and life sciences. The firm identifies, invests in, and builds high-growth, IP-rich companies with an international portfolio, focusing on sectors including industrial technology, healthcare, and sustainability. It employs a capital-efficient investment strategy that combines syndicated investments, direct balance sheet funding, and managed funds to support companies from their early stages through to successful exit. EMV Capital engages in proactive portfolio management, often taking board positions and working closely with company leadership. It provides extensive value creation services, including support for fundraising, exit readiness, IP strategy, and corporate collaborations, to drive growth and maximize returns for investors through strategic exits.

Recent filings

Filing Released Lang Actions
Netscientific Appoints Ian Postlethwaite as CFO
Board/Management Information Classification · 100% confidence The document is an official announcement from NetScientific PLC regarding the appointment of a new Chief Financial Officer (Ian Postlethwaite). It details his professional background, current and past directorships, and includes quotes from the Chairman and the appointee. This falls squarely under the category of board or management changes.
2016-04-05 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from NetScientific PLC titled 'Notice of Results'. It informs the market that the company will release its final results for the year ended 31 December 2015 on a future date (07 April 2016). According to the 'Menu vs Meal' rule, an announcement regarding the timing or publication of a report is classified as a Report Publication Announcement (RPA).
2016-03-24 English
Adoption of reduced disclosure framework
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from NetScientific plc regarding a change in accounting framework (adoption of FRS 102). It is a regulatory notification to shareholders about accounting policy changes and disclosure exemptions, which does not fit into specific categories like financial reports, dividends, or M&A. Therefore, it is classified as a general regulatory filing.
2016-03-07 English
Wanda and Dignity Health launch OncoVerse platform
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) regarding a new partnership between NetScientific PLC's subsidiary, Wanda, and Dignity Health. It details a business development/commercial agreement rather than a financial report, dividend, or governance update. Since it is a general regulatory announcement regarding company operations and partnerships that does not fit into more specific categories like M&A or financial reporting, it is classified as a Regulatory Filing (RNS).
2016-02-29 English
NetScientific appoints Prof. Stephen Smith as NED
Board/Management Information Classification · 100% confidence The document is an official announcement from NetScientific PLC regarding the appointment of Professor Stephen Smith as a Non-Executive Director. It details his professional background, committee assignments, and provides required regulatory disclosures under AIM Rules. This fits the definition of a Board/Management Information announcement.
2016-02-17 English
PDS Biotechnology partners with NCI
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding a partnership between NetScientific PLC's portfolio company, PDS Biotechnology, and the National Cancer Institute. It is a corporate news release detailing a clinical trial collaboration. Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a standard regulatory announcement, it is classified as RNS.
2016-02-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.